FDA Accepts BLA for AVT16, Proposed Vedolizumab Biosimilar
The BLA acceptance marks a regulatory milestone for the gut-inflammation biologics pipeline, with biosimilar competitio…
The BLA acceptance marks a regulatory milestone for the gut-inflammation biologics pipeline, with biosimilar competitio…
As bioactive ingredient validation demands tighten, contract development organizations with end-to-end analytical infra…
The CDMO's integrated testing infrastructure targets a critical bottleneck in biologics development: closing the gap be…
The Dutch CDMO signals growing demand for end-to-end analytical support as biotech sponsors accelerate vaccine and biol…
As Asia-Pacific milk tea culture collides with functional formulation trends, regional brands are staking out different…
Hepatocyte-directed vesicle technology positions the delivery platform at the intersection of pharma and advanced nutra…
Results published simultaneously in NEJM and Nature Medicine signal a new mechanistic benchmark for metabolic-health fo…
With BHB blends flooding e-commerce channels, operators and formulators face mounting pressure to substantiate ketone-d…
As the men's wellness segment expands, operators and formulators face tightening expectations around evidence-based pos…
Early-phase data presented at EULAR 2026 positions B-cell depletion as a credible mechanism in autoimmune disease manag…
New data across three high-complexity populations could reshape how formulators and clinicians think about insulin-deli…
As the metabolic health ingredient space watches GLP-1 mimetic botanicals gain shelf space, pharma-grade peptide data c…